CSPG4:未分化甲状腺癌的潜在免疫治疗靶点
本研究通过未分化甲状腺癌(ATC)患者来源异种移植小鼠与自体外周血T细胞实验,并采用质谱鉴定HLA-DQ复合物洗脱肽,发现CSPG4来源肽在ATC中丰度高且特异。CSPG4在侵袭性甲状腺癌中表达显著升高,与肿瘤大小、腺外侵犯及ICAM-1环周表达相关,其mRNA过表达与ATC及低分化甲状腺癌更差的总生存相关。
要点
- CSPG4在ATC中表达显著升高,多数ATC细胞系平均荧光强度约高10倍。
- CSPG4表达与肿瘤大小、腺外侵犯及ICAM-1环周表达相关。
- CSPG4 mRNA过表达与ATC和低分化甲状腺癌更差总生存相关。
核心结论
- CSPG4在侵袭性甲状腺癌中表达显著升高,与不良预后强相关,并具作为ATC新型免疫治疗靶点的潜力。
研究设计与样本
- 研究采用ATC患者来源异种移植小鼠加自体外周血T细胞,并以质谱鉴定ATC患者来源细胞HLA-DQ复合物洗脱肽。
- 用流式细胞术分析甲状腺癌细胞系与原代细胞培养的CSPG4表面表达,用免疫组化比较ATC、乳头状甲状腺癌与正常甲状腺组织的表达及定位。
- 分析CSPG4表达与甲状腺癌患者临床病理特征的相关性。
主要发现
- ATC组织HLA-DQ表达水平高,患者CD4+ T细胞暴露于ATC时显示激活。
- ATC组织HLA-DQ复合物洗脱物中CSPG4来源肽为最丰富且特异的肽之一。
- 流式细胞术显示甲状腺癌细胞表面CSPG4表达显著高,多数ATC细胞系平均荧光强度约高10倍。
- 多数ATC患者肿瘤细胞胞质或膜表达CSPG4。
- CSPG4表达与肿瘤大小、腺外侵犯及ICAM-1环周表达相关,其mRNA过表达与ATC和低分化甲状腺癌更差总生存相关。
临床怎么用
- 可将CSPG4作为ATC免疫治疗候选靶点进一步验证,并关注其与肿瘤大小、腺外侵犯及ICAM-1环周表达的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Anaplastic thyroid cancer (ATC) is a rare cancer with poor prognosis and few treatment options. The objective of this study was to investigate new immune-associated therapeutic targets by identifying ATC-derived, human leukocyte antigen (HLA) class II-presenting peptides. One protein that generated multiple peptides in ATC was chondroitin sulfate-proteoglycan-4 (CSPG4), a transmembrane proteoglycan with increased expression in multiple aggressive cancers, but not yet investigated in ATC. Methods: We applied autologous peripheral blood T cells to ATC patient-derived xenografted mice to examine whether ATC induces a tumor-specific T cell response. We then identified peptide antigens eluted from the HLA-DQ complex in ATC patient-derived cells using mass spectrometry, detecting abundant CSPG4-derived peptides specific to the ATC sample. Next, we analyzed the surface expression level of CSPG4 in thyroid cancer cell lines and primary cell culture using flow cytometry. In addition, we used immunohistochemistry to compare the expression level and localization of the CSPG4 protein in ATC, papillary thyroid cancer, and normal thyroid tissue. We then investigated the correlation between CSPG4 expression and clinicopathological features of patients with thyroid cancer. Results: We found that ATC tissue had a high level of HLA-DQ expression and that the patient's CD4+ T cells showed activation when exposed to ATC. By eluting the HLA-DQ complex of ATC tissue, we found that CSPG4 generated one of the most abundant and specific peptides. CSPG4 expression at the cell surface of thyroid cancer was also significantly high when determined by flow cytometry, with the majority of ATC cell lines exhibiting ∼10-fold higher mean fluorescence intensity. Furthermore, most ATC patient cases expressed CSPG4 in the cytoplasm or membrane of the tumor cells. CSPG4 expression was correlated with tumor size, extrathyroidal extension, and intercellular adhesion molecule-1 (ICAM-1) circumferential expression. CSPG4 mRNA overexpression was associated with worse overall survival in patients with ATC and poorly differentiated thyroid cancer. Conclusions: CSPG4 expression is significantly elevated in aggressive thyroid cancers, with a strong correlation with a poor prognosis. The vast number of HLA-DQ eluted CSPG4 peptides was identified in ATC, demonstrating the potential of CSPG4 as a novel immunotherapeutic target for ATC.
引用
- Egan CE, Stefanova D, Ahmed A, et al. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer. Thyroid. 2021. PMID: 34078123. doi:10.1089/thy.2021.0067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。